|search over 1,000 Venture Capital related sites|
|1.||Kodiak Venture Partners (74%):|
Dave Furneaux Lou Volpe John Abraham Chris Greendale Elliot Katzman Chip Meakem Mike Schiavo Murray Berkowitz Penny Breen Luciana Castro Steve Maxwell The Team Mike Schiavo General Partner & Chief Financial Officer Background: Mike has been active in private equity-related activities since 1983. Pri...
|2.||HORIZONTE VENTURE MANAGEMENT GmbH (74%):|
Management Dr. Franz Krejs Dr. Alfred Matzka Dr. Matej Penca Dr. Franz R. Krejs Dr. Franz R. Krejs, Managing Partner , Vienna has set up Horizonte in 1985. Dr. Krejs studied applied physics at the Technical University in Vienna and obtained a doctorate in physics (Ph.D.) from the University of Penn...
|3.||CapitalVenue Massachusetts (65%):|
Venture Investors that have worked with CapitalVenue Home | Events | TeamVenue | Programs | "New" Newsletter | Contact us The following list of venture investors have participated in CapitalVenue's Past Events Adams Harkness and Hill Ventures Advanced Technology Program, NIST Advent Intern...
|4.||CrossBridge Venture Partners: Fund Manager-Shinji Miyashita (62%):|
Shinji Miyashita- General Partner Mr. Miyashita joined Techno-Venture Co., Ltd. as an Investment Manager (General Partner equivalent) in 1988. His past investments at Techno-Venture include: Network Express, Inc., (acquired by Cabletron and later spun-off to become Avail Networks, Inc.), Quickturn ...
|5.||CrossBridge Venture Partners: Fund Manager-Takaharu Yamagami (59%):|
Takaharu Yamagami- General Partner Mr. Yamagami joined Techno-Venture Co., Ltd. as the General Manager (General Partner equivalent) of the Investment Department, Venture Capital Division in 1997. Techno-Venture is Japan's oldest venture capital company. The Company's funds hold investments in over ...
|6.||Essex Woodlands News (58%):|
Confluent Surgical, Inc. Raises $20 Million in Series-C financing Waltham, MA, June 25, 2002 -- Confluent Surgical, Inc., today announced that it has completed a $20 million Series C round of venture funding, led by Essex Woodlands Health Ventures. Other venture investors participating in this finan...
|7.||Easton Capital Investment Group::Genetix Pharmaceuticals, Inc. (53%):|
Genetix Pharmaceuticals, Inc. Genetix is a gene therapy company with a cutting edge gene transfer technology platform (LentiPak ) for the effective therapeutic human delivery of corrective genes for genetic blood disorders and severe chronic human diseases. The Company's lead product, LentiGlobin , ...
|8.||EARLYBIRD | Venture Capital (47%):|
Date Portfolio Exit September 2005 Esmertec AG www.esmertec.com IPO (SWX: ESMN) September 2005 Interhyp AG www.interhyp.de IPO (Prime Standard Frankfurt Exchange: IYP) April 2004 Element 5 AG www.element5.com Trade Sale to Digital River, Inc. (NASDAQ: DRIV) September 2003 kiwilogic.com AG www.kiwil...
|9.||EARLYBIRD | Venture Capital (47%):|
Datum Portfolio Exit September 2005 Esmertec AG www.esmertec.com IPO (SWX: ESMN) September 2005 Interhyp AG www.interhyp.de IPO (Prime Standard der Frankfurter B rse: IYP) April 2004 Element 5 AG www.element5.com Verkauf an Digital River, Inc. (NASDAQ: DRIV) September 2003 kiwilogic.com AG www.kiwi...
|10.||EARLYBIRD | Venture Capital (45%):|
Sunday October 2, 2005 More Courageousness for the Risk (Text in German) Junge Unternehmer finden wieder Financiers, und das Umfeld f r Neuemissionen an der B rse ist gut. Privatanleger k nnen daran teilhaben von Christina Anastassiou Christian Nagel und seine Kollegen vom Hamburger Risikokapitalgeb...
|11.||Easton Capital Investment Group::Transave, Inc (41%):|
Transave, Inc. Transave is a biotechnology company that treats pulmonary diseases via their proprietary inhaled lipid complexed/liposomal drug delivery technology. The Company's SLIT technology enables both sustained release and enhanced targeting of therapeutic compounds to the diseased areas of th...
|12.||GreenHills Ventures (39%):|
Investors: Login | Businesses: Submit Plan GreenHills Ventures, LLC., combines extensive advisory experience with strategic initiatives. We focus on providing strong fundamentals to facilitate sound business execution. GreenHills Ventures, LLC., has developed an extensive network of Fortune 1000 co...
|13.||Investment Partners (39%):|
W e have invested with a number of funds, including such colleagues as: Allied Capital Corp Austin Ventures Bell Canada Ventures Blue Chip Venture Company Boulder Ventures Grotech Capital Group Intel Capital Intersouth Partners Kodiak Venture Partners MacAndrews & Forbes Mid Atlantic Venture Funds N...
|14.||Easton Capital Investment Group::TransMolecular, Inc. (35%):|
TransMolecular, Inc. TransMolecular is a neuroscience biotechnology company developing a new class of targeted anti-cancer therapeutics and imaging agents based on a peptide called chlorotoxin. The Company's lead product, 131I-TM-601, has completed Phase I/II clinical trials for the treatment of adu...
|15.||EVP - Portfolios by sector/country (34%):|
EVP II PORTFOLIO BY COUNTRY GERMANY Sector: Communications Formed in January 2001, CoreOptics develops and manufactures subsystems for ultra high-speed optical networking applications. Their current portfolio includes 2 fully qualified, distortion tolerant 10Gbps and 40Gbps transponders for Metro, ...
|16.||easton Capital Investment Group::Acorda Therapeutics (33%):|
"In May 2003, Easton led a $55.3 million financing for Acorda Therapeutics, one of the top three private biotechnology financings to date in 2003. Easton s ability to lead such a significant round, particularly in a challenging financial environment, is a testament to its capabilities and excel...
|17.||European Investment Fund (32%):|
ERP-EIF Community Search Home Sitemap Contact </div About EIF Info & News Venture Capital ERP-EIF Dachfonds Focus & Approach Criteria & Process ERP-EIF Team/Contact ERP-EIF Community Portfolio Guarantees <A CLASS="netscape47" HREF="/highvap/" onMouseOver="window.status='High Value Added Produc...
|18.||European Investment Fund (31%):|
ERP-EIF Team/Contact Search Home Sitemap Contact </div About EIF Info & News Venture Capital ERP-EIF Dachfonds Focus & Approach Criteria & Process ERP-EIF Team/Contact ERP-EIF Community Portfolio Guarantees <A CLASS="netscape47" HREF="/highvap/" onMouseOver="window.status='High Value Added Pro...
|19.||CrossBridge Venture Partners Track Record: Past experience with Silicon Valley Bank, JAFCO, and Techno-Venture. (29%):|
Track Record Since December 1986 through December 1999, the Fund Managers, while managing portfolios for Silicon Valley Bank, JAFCO, and Techno-Venture, have committed to invest $182.8 million in venture equity and venture debt in 95 companies. The aggregate net internal rate of return ("IRR&q...
|20.||CrossBridge Management: Experienced in venture capital, venture banking, technology lending and corporate finance in U.S. and Japan. (29%):|
Management The four equal Fund Managers are experienced in venture capital, venture banking, technology lending, and corporate finance in both Japan and the United States. The Fund Managers come from leading venture firms including Silicon Valley Bank, JAFCO, and Techno-Venture. Over the past five ...